Feprazone: Absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects

T. Meloni, G. Forteleoni, M. Serra, S. Daniotti, L. Negri, P. Giuntini, L. Canepa, G. F. Gaetani

Research output: Contribution to journalArticlepeer-review


Some drugs, including nonsteroidal antiinflammatory compounds, can be hemolytic in glucose-6-phosphate dehydrogenase-deficient patients. We have studied the potential hemolytic activity of feprazone, a nonsteroidal antiinflammatory compound in vitro and in vivo. Agents that may be hemolytic for glucose-6-phosphate dehydrogenase-deficient erythrocytes will stimulate the hexose monophosphate shunt in normal erythrocytes. Eleven normal subjects were treated with feprazone and their erythrocytes were incubated in their own sera (containing active feprazone metabolites) and [1-14C]-glucose. Because no statistically significant increase in 14CO2 evolution was observed, 15 pediatric male patients with glucose-6-phosphate dehydrogenase deficiency who required antiinflammatory treatment were treated with feprazone. No hemolytic crises and no statistically changes of hematologic tests were observed.

Original languageEnglish
Pages (from-to)418-420
Number of pages3
JournalJournal of Clinical Pharmacology
Issue number8-9
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Feprazone: Absence of hemolytic effects in glucose-6-phosphate dehydrogenase-deficient subjects'. Together they form a unique fingerprint.

Cite this